Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from 3D Medicines, Inc. ( (HK:1244) ) is now available.
3D Medicines Inc. has announced the appointment of Mr. Ding Gan as the new Chief Commercial Officer. With over 30 years in the pharmaceutical and biotechnology sectors, Mr. Ding brings extensive experience in oncology pipeline planning, product commercialization strategies, and managing commercial operations. His past roles include senior positions at Eli Lilly, GlaxoSmithKline, Cardinal Health, and Mylan Pharmaceuticals China, highlighting his expertise in global and market-specific strategies. This appointment is expected to strengthen 3D Medicines’ commercial operations and strategic development in the pharmaceutical market.
More about 3D Medicines, Inc.
3D Medicines Inc. is a company operating in the pharmaceutical and biotechnology industry, focusing on product commercialization and lifecycle management. The company, incorporated in the Cayman Islands, is publicly traded on the Hong Kong Stock Exchange.
YTD Price Performance: -2.60%
Average Trading Volume: 546,660
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$774.6M
For an in-depth examination of 1244 stock, go to TipRanks’ Stock Analysis page.